Thu, May 17, 2012
GSK melanoma drug shows promise in early trial
By Kate Kelland
LONDON (Reuters) - An experimental cancer drug developed by Britain's GlaxoSmithKline may add vital months to the lives of melanoma patients ...
Thu, May 17, 2012
Sex, age may affect athletes' concussion recovery
(Reuters) - Female and high school athletes may need more time to recover from a concussion than their male or college counterparts, according to a ...
Thu, May 17, 2012
New York judge with cancer makes case for marijuana
By Jessica Dye
NEW YORK (Reuters) - A cancer-stricken judge in New York has become an unlikely voice in support of legalizing the use of ...
Thu, May 17, 2012
Breastfed babies may gain less weight
By Andrew M. Seaman
NEW YORK (Reuters Health) - Babies who are fed milk from their mothers' breasts gain less weight over their first year ...
Thu, May 17, 2012
Canada OKs Osiris drug; first stem cell therapy
By Toni Clarke
BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease ...
Thu, May 17, 2012
Fewer girls completing all three HPV shots: study
By Kerry Grens
NEW YORK (Reuters Health) - Among girls and women who get their first human papillomavirus, or HPV, vaccine, the percent who complete ...
Thu, May 17, 2012
South Carolina woman battles flesh-eating bacterial disease
By Harriet McLeod
CHARLESTON, South Carolina (Reuters) - A new mother of twins in Greenville, South Carolina, is the latest victim of a rare and ...
Thu, May 17, 2012
Sex, age may affect athletes' concussion recovery
By Amy Norton
NEW YORK (Reuters Health) - Female and high school athletes may need more time to recover from a concussion than their male ...
Thu, May 17, 2012
Safety inspections don't hurt businesses-study
By Scott Malone
BOSTON (Reuters) - Random inspections of U.S. industrial workplaces lower the risk of workers being injured on the job and have ...
Thu, May 17, 2012
Human Genome adopts rights plan to ward off Glaxo
(Reuters) - Human Genome Sciences Inc said on Thursday it adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 ...
Recent Comments